Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 8/20 | 0.67 |
| ▸ | CHRND | Q07001 | 5/20 | 0.65 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.65 |
| ▸ | CHRNG | P07510 | 1/20 | 0.65 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19365102 | 0.91 | GRIA1 (0.61) | GRIA1CHRNDCHRNA1CHRNGCHRNB1 | |
| SCHEMBL16508342 | 0.91 | GRIA1 (0.61) | GRIA1CHRNDCHRNA1CHRNGCHRNB1 | |
| SCHEMBL19365101 | 0.91 | GRIA1 (0.61) | GRIA1CHRNDCHRNA1CHRNGCHRNB1 | |
| SCHEMBL19102175 | 0.91 | GRIA1 (0.61) | GRIA1CHRNDCHRNA1CHRNGCHRNB1 | |
| SCHEMBL13299950 | 0.90 | GRIA1 (0.60) | GRIA1CHRNDCHRNA1CHRNGCHRNB1 | |
| SCHEMBL16360382 | 0.90 | GRIA1 (0.60) | GRIA1CHRNDCHRNA1CHRNGCHRNB1 | |
| SCHEMBL19372617 | 0.87 | GRIA1 (0.59) | GRIA1CHRNDCHRNA1CHRNGCHRNB1 | |
| SCHEMBL24048945 | 0.83 | GRIA1 (0.52) | GRIA1CHRNDCHRNA1CHRNGCHRNB1 | |
| SCHEMBL21186351 | 0.82 | CHRND (0.58) | GRIA1CHRNDCHRNA1CHRNGCHRNB1 | |
| SCHEMBL21186271 | 0.82 | GRIA1 (0.51) | GRIA1CHRNDCHRNA1CHRNGCHRNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10870664-B2 | Nitrogen-containing macrocyclic conjugates as radiopharmaceuticals | THE UNIVERSITY OF MELBOURNE (AU) | 2020-12-22 | — | — | US | disclosed |
| US-20190225625-A1 | NITROGEN-CONTAINING MACROCYCLIC CONJUGATES AS RADIOPHARMACEUTICALS | Clarity Pharmaceuticals Ltd (AU) | 2019-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10870664-B2 | Nitrogen-containing macrocyclic conjugates as radiopharmaceuticals | NCL, NUDC, C3AR1 | GRIA1 1840/4885CHRND 3598/4885CHRNA1 4041/4885 |
| US-20190225625-A1 | NITROGEN-CONTAINING MACROCYCLIC CONJUGATES AS RADIOPHARMACEUTICALS | NCL, NUDC, C3AR1 | GRIA1 1840/4885CHRND 3598/4885CHRNA1 4041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.